Navigation Links
Pharmaceutical Patent Sale of First-in-Class Compounds to Treat Women's Health Needs
Date:8/30/2013

PRINCETON, N.J., Aug. 30, 2013 /PRNewswire/ -- IP Shakti has partnered with a California pharmaceutical company to market patent assets corresponding to three new therapeutics to treat women's health needs. This is a unique opportunity for large and small bio-medical research and development companies to access patent assets related to first-in-class therapeutic compounds that are currently in clinical development.

Menerba is a first-in-class treatment for hot-flashes experienced during menopause. In Phase I and II clinical trials, patients taking Menerba were 2.3 times more likely to have a 50% reduction in the number of hot flashes experienced, with no severe adverse effects compared to those receiving the placebo. The safety and tolerability profile was found to be favorable and superior to existing hormone replacement therapies. The Chemistry, Manufacturing and Controls review has been approved by the U.S. Food and Drug Administration, as required to begin Phase III clinical trials. The compound has strong intellectual property protection, with 38 patents covering the composition of matter, structure-function, and therapeutic use. These patents provide intellectual property protection through 2026.

Bezielle is a novel treatment for hormone independent metastatic breast cancer. The results of Phase I clinical trials indicate that Bezielle has excellent tolerability and minimal toxicity. The results of early-stage clinical trials indicate that the compound will be particularly effective in patients that have failed other treatments. Additionally, pre-clinical research tests indicate that the compound may be effective for treating pancreatic cancer. There are six patents covering the compound as a monotherapy for treating breast cancer. 

Seala is a non-steroidal treatment for vaginal atrophy associated with menopause. Comprehensive pre-clinical testing has been completed, and the compound is ready to advance to Phase I and II clinical trials. There are seven patents covering the compound and method of therapeutic use.

Approximately 40 million women transition through menopause annually, and 80% experience severe symptoms including hot flashes and vaginal atrophy. Currently, 90 million prescriptions are filled for hormone replacement therapies to treat these conditions. However, those hormone replacement therapies have severe side effects and many have black box warnings. Novel treatments that are not associated with serious side effects have significant market potential. The sale of patents for three promising therapeutic compounds to treat hot flashes, vaginal atrophy, and breast cancer offer important research and development opportunities to develop first-in-class therapeutics that are safer and more effective than existing therapies.

The experienced team at IP Shakti consists of intellectual property experts who have strong backgrounds in biotechnology asset transactions through both private sales and auctions. This partnership has employed the latest in patent valuation tools and analysis to ensure access to concrete data about the patented compounds and the strength of the intellectual property.

About the company: IP Shakti is an early-stage seed fund for biomedical and life science innovations. President and CEO Dr. Dipanjan Nag is leading the effort in the large-scale pharma compound sale, utilizing his experience as a former Director and Vice President at ICAP Ocean Tomo. While at ICAP he concentrated on private sales of biotechnology and life sciences as well as being responsible for private sales, patent auctions, and valuations of intellectual property assets. 

http://www.ipshakti.com

For more information please contact: Michael Chiu, Email or (609) 759-0214

See more news at IP Shakti.


'/>"/>
SOURCE IP Shakti
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  AfterPill.com is reporting that this week,s ... for all women who are at risk of unintended ... year and raises the risks of unprotected sex in ... According to the Guttmacher Institute, there are 43 ... child-bearing age, who have sex without the intention of ...
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... MEADOWS , Ill. and INDIANAPOLIS , ... milestone for many young people, but for those with ... Not only do these students juggle class schedules, assignments ... of living with type 1 diabetes. On top of ... first time. Diabetes Scholars Foundation (Foundation) ...
Breaking Medicine Technology:
(Date:2/11/2016)... Alpharetta, Georgia (PRWEB) , ... February 11, 2016 ... ... Physicians Group (DMPG) will use the action analytics leader’s population health solutions, ... analytics and clinical support to the Atlanta-area healthcare system. Details of the contract ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s ... of cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. ... cosmetic procedures. One of the most common procedures he performs is his natural ...
(Date:2/11/2016)... ... 2016 , ... Image One USA veteran franchise owner Maria Bogacki ... buildings of Nashville that will benefit. , “I’ve enjoyed being a part of the ... was no question that I would bring my business with me,” Bogacki said. “The ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... to reverse diabetes has been gearing up for their simultaneous grand openings in ... It’s about right now that you’re probably wondering, is reversing diabetes possible? According ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper ... surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance ... for rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage ...
Breaking Medicine News(10 mins):